Myelofibrosis: Thalidomide Finds a New Disease

Silver, Richard T.
July 2004
Mayo Clinic Proceedings;Jul2004, Vol. 79 Issue 7, p857
Academic Journal
Editorial. Comments on a study on the long-term outcome of thalidomide treatment of myelofibrosis with myeloid metaplasia. Mechanism of action of thalidomide; Responses in the cellular phase of the condition; Therapeutic contribution in terms of quality of life.


Related Articles

  • Durable Response to Thalidomide-Based Drug Therapy for Myelofibrosis with Myeloid Metaplasia. Mesa, Ruben A.; Elliott, Michelle A.; Schroeder, Georgene; Tefferi, Ayalew // Mayo Clinic Proceedings;Jul2004, Vol. 79 Issue 7, p883 

    Objective: To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with myeloid metaplasia (MMM). Patients and methods: We analyzed (March 1999 to August 2003) initial and long-term outcomes from 36...

  • CORRIGENDUM.  // Biologics: Targets & Therapy;2013, Vol. 7, p231 

    A correction to the article "Treatment and management of myelofibrosis in the era of JAK inhibitors," by C. Keohane, D. H. Radia, and C. N. Harrison that was published in the issue is presented.

  • JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni // New England Journal of Medicine;3/1/2012, Vol. 366 Issue 9, p787 

    Background: Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. Methods: We assigned 219 patients with...

  • Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Pardanani, A // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1449 

    The author discusses the pros and cons of ruxolitinib for the treatment of myelofibrosis. The author mentions a clinical trial which supports that ruxolitinib could be the best available therapy for the management of the said disease. The author states that short-term and long-term...

  • Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis. Lisette, Del Corso; Enrico, Balleari; Eleonora, Arboscello; Riccardo, Ghio; Manlio, Mencoboni; Omar, Racchi // Case Reports in Hematology;2013, p1 

    Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is...

  • Janus kinase inhibitors in myeloproliferative neoplasms. Bazargan, Ali; Tam, Constantine // Australian Prescriber;Oct2014, Vol. 37 Issue 5, p161 

    Hyperactive Janus kinase 2 signalling is a key molecular event in polycythaemia, essential thrombocythaemia and myelofibrosis. This is associated with the V617F mutation in the Janus kinase 2 gene of many patients with myeloproliferative disease. Ruxolitinlb is the first Janus kinase Inhibitor...

  • Central neuraxial blockade for splenectomy in myeloproliferative disease: A word of caution. Myatra, S. N.; Kothekar, A.; Siddiqui, S. S.; Divatia, J. V. // Indian Journal of Anaesthesia;Oct2015, Vol. 59 Issue 10, p670 

    We describe management of portal vein thrombosis (PVT) in a patient with myeloproliferative disease after splenectomy. This case posed a unique therapeutic challenge in maintaining a fine balance between life-saving thrombolysis and the risk of neuraxial complications due to bleeding. The...

  • Profile of pomalidomide and its potential in the treatment of myelofibrosis. Gowin, Krisstina L.; Mesa, Ruben A. // Therapeutics & Clinical Risk Management;2015, Vol. 11, p549 

    Myelofibrosis, a Philadelphia-negative myeloproliferative neoplasm, is in a new treatment era after the discovery of the JAK2V617F mutation in 2005. JAK inhibitors boast improvements in disease-related symptoms, splenomegaly, and overall survival; however, treatment of myelofibrosis remains a...

  • Ruxolitinib has a positive impact on QOL in myelofibrosis patients.  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p9 

    The article discusses research on the efficacy of ruxolitinib versus best available therapy on health-related quality of life (QOL) and symptoms in myelofibrosis patients with an intermediate- to high-risk prognosis, referencing a study published in the 53rd Annual Meeting and Exposition of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics